These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 17611572)
81. Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis. Samuelson B; Chai-Adisaksopha C; Garcia D J Thromb Thrombolysis; 2015 Nov; 40(4):474-9. PubMed ID: 25894476 [TBL] [Abstract][Full Text] [Related]
82. Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium. Tefferi A; Abdel-Wahab O; Cervantes F; Crispino JD; Finazzi G; Girodon F; Gisslinger H; Gotlib J; Kiladjian JJ; Levine RL; Licht JD; Mullally A; Odenike O; Pardanani A; Silver RT; Solary E; Mughal T Blood Cancer J; 2011 Mar; 1(3):e7. PubMed ID: 23471017 [TBL] [Abstract][Full Text] [Related]
83. Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea. Renso R; Aroldi A; Pioltelli P; Gambacorti-Passerini C; Elli EM Blood Cancer J; 2018 Jun; 8(6):56. PubMed ID: 29891835 [No Abstract] [Full Text] [Related]
84. Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience. Begna K; Abdelatif A; Schwager S; Hanson C; Pardanani A; Tefferi A Blood Cancer J; 2016 May; 6(5):e427. PubMed ID: 27232929 [No Abstract] [Full Text] [Related]
85. Bendamustine therapy associated resolution of anemia and splenomegaly in myelofibrosis. Tefferi A; Cerquozzi S; Liaw J Am J Hematol; 2016 Feb; 91(2):E6-7. PubMed ID: 26587685 [No Abstract] [Full Text] [Related]
90. Bone marrow aplasia after pipobroman: an immune-mediated mechanism? Triffet A; Straetmans N; Ferrant A Br J Haematol; 2001 Dec; 115(3):713-4. PubMed ID: 11736962 [No Abstract] [Full Text] [Related]
91. Essential thrombocythemia: a retrospective study on the clinical course of 100 patients. Chistolini A; Mazzucconi MG; Ferrari A; la Verde G; Ferrazza G; Dragoni F; Vitale A; Arcieri R; Mandelli F Haematologica; 1990; 75(6):537-40. PubMed ID: 2098295 [TBL] [Abstract][Full Text] [Related]
92. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617 [TBL] [Abstract][Full Text] [Related]
93. [Diagnosis and treatment of essential thrombocythemia]. Kuramoto A Rinsho Ketsueki; 1995 May; 36(5):480-6. PubMed ID: 7783354 [TBL] [Abstract][Full Text] [Related]
94. The management of elderly patients with myeloproliferative disorders. Tura S Hematol Oncol; 1993; 11 Suppl 1():39-41. PubMed ID: 8486340 [No Abstract] [Full Text] [Related]